相关实验视频
Updated: May 8, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
早期的突触病理与阿尔茨海默氏症疾病中小的tau聚合物有关
Emre Fertan1,2,3, Shekhar Kedia4,5, George Nolan6
1Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK. ef417@cam.ac.uk.
Acta neuropathologica
|January 23, 2026
概括
早期阿尔茨海默氏症 (AD) 涉及突触内的小聚合物,先于纠形成. 这些突触聚合物生长并与驱动神经炎症和AD进展中的突触损失的细胞信号相关联.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 的特点是记忆力丧失,与tau聚合和突触功能障碍有关.
- 病理,包括聚合,是阿尔茨海默病的标志,但其早期突触存在和特征尚未完全理解.
研究的目的:
- 在阿尔茨海默氏病 (AD) 病例和对照中,在单个突触体内特征化纳米图聚合物.
- 在AD进展过程中调查突触聚合物的大小,数量和分子关联.
- 阐明突触病理在早期AD病变发生和微质介导突触损失中的作用.
主要方法:
- 使用SynPull和直接随机光学重建显微镜 (dSTORM) 进行突触体隔离和表征.
- 聚合物特定单分子阵列 (SIMOA) 与蛋白酶K消化进行确认.
- 三维超分辨率显微镜 (STED) 和免疫组织化学分析的酸化,与酸丁素,CD47,和synaptogyrin-3.
主要成果:
- 在约3%的对照突触体中发现了AT8阳性tau聚合物,在布拉克阶段6.0时增加到约20%.
- 突触病理在布拉克3期被检测到,在前额叶皮层之前形成.
- 总体大小随着AD的进展而增加 (在第0阶段为117nm,在第6阶段为182nm),但在很大程度上仍然没有延长.
- 在第3阶段观察到AT8阳性与T181,酸和synaptogyrin-3的同局定位增加,CD47同局定位减少.
结论:
- 在阿尔茨海默氏病的发病过程中,即使在显著的结形成之前,也存在着小的,内突触的聚体.
- 突触聚合物的大小和分子关联随着疾病的进展而变化,影响突触功能.
- 早期的突触病理,以特定的分子相互作用为特征,可能会导致阿尔茨海默病中微质驱动的突触损失.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

